In this cohort of women living with HIV (WLWH) in Rwanda, there was an increased risk of delivering a low birth weight (LBW) ...

Curry and colleagues tested an artificial intelligence (AI) software that guided non-radiology specialists in diagnosing ...

In this systematic review and meta-analysis, estimated blood pressure was found to vary significantly between different ...

In this microsimulation model of patients with high cardiovascular risk, an intensive systolic blood pressure (SBP) target of ...

Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant ...

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety concerns led to an ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes 1. In this cohort of ...

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...